Real Cases
Documented treatment journeys from our affiliated hospitals in China — diagnosis, decision-making, protocol, timeline and outcome. Every case is published with the family's authorisation.
Solid Tumor · CAR-T Therapy · 14 September 2026
World’s First International Solid Tumor CAR-T Patient Completes Treatment at Jiahui International Cancer Center
Josh, a 59-year-old patient from New Zealand with advanced gastroduodenal adenocarcinoma, travelled to Shanghai for Claudin 18.2-targeted Satri-cel (CT041) CAR-T therapy after chemotherapy and immunotherapy failed to stop his disease. Following treatment at Jiahui International Cancer Center, his severe malignant ascites resolved by Day 10 and he returned home with coordinated cross-border follow-up.
Read the full case →
Paediatric Lymphoma · Targeted Therapy · 19 August 2026
Patient Voices | A 13-year-old boy with ALK-positive anaplastic large cell lymphoma: three years in CR, back at school and into university
In the winter of 2018, 13-year-old Qinqin was diagnosed with ALK-positive anaplastic large cell lymphoma. Treated on an adult protocol at another hospital, he went through chemotherapy, autologous transplant and targeted therapy, reached complete remission only late, and missed key drugs such as vinblastine and MTX. In December 2019 his parents brought him to Beijing GoBroad Boren Hospital, to the paediatric lymphoma team of Prof. Zhang Yonghong and Dr Zhu Qing. On an individualised, standardised paediatric protocol he recovered steadily — he remains in continuous complete remission and has now been off treatment for three and a half years. This September, with a score of over 540, he entered the mathematics department of a first-tier university.
Read the full case →
CAR-T · Transplant · International Patient · 10 August 2026
Margarita's Journey: Overcoming Leukaemia Across Borders
Margarita, a patient from Russia, was diagnosed with T-cell acute lymphoblastic leukaemia (T-ALL), an aggressive and highly complex blood cancer. After standard chemotherapy failed to control the disease, she came to GoBroad Healthcare Group (GHG) in China, where the team designed a precise plan combining CAR-T cell therapy with haematopoietic stem cell transplantation. She achieved a positive treatment response, was safely discharged and has returned to Russia for local follow-up care.
Read the full case →
CAR-T · Paediatric Leukaemia · 29 July 2026
Patient Voices | A 10-year-old girl with T-ALL achieves durable remission after allogeneic CD5 CAR-T therapy
Relapsed, refractory and progressing T-cell acute lymphoblastic leukaemia in a 10-year-old girl. Fourteen days after an infusion of donor-derived (father) CD5 CAR-T cells at Beijing GoBroad Hospital she was in complete remission; after transplant, her latest work-up shows negative CSF and marrow flow cytometry, negative fusion genes and 100% peripheral blood chimerism.
Read the full case →
CAR-T · Lymphoma · 5 July 2026
Patient Voices | A New Step Forward After Multiple Relapses
Vasilii, 35, had stage IV high-risk diffuse large B-cell lymphoma that relapsed after chemotherapy, autologous and allogeneic stem cell transplantation and a previous CAR-T therapy. At GoBroad Healthcare Group, Dr. Shaomei Feng's team designed an individualised plan with targeted conditioning followed by CD79b CAR-T and CD19/CD22 CAR-T cell therapy. His condition improved and he was safely discharged for follow-up care.
Read the full case →
CAR-T · Multiple Myeloma · 15 June 2026
Patient Voices | Repeatedly progressing multiple myeloma reaches complete remission after CAR-T therapy
Ms. Zhang, a 55-year-old teacher of more than 30 years, was diagnosed with IgD λ multiple myeloma in 2022. Standard chemotherapy achieved only a partial response and she could not tolerate immunomodulatory drugs; her disease progressed several times within three years. After an autologous transplant at Shanghai GoBroad Liquan Hospital, her IgD rose again in 2025. In September 2025 Dr. Li Su's team treated her with a licensed BCMA CAR-T product (equecabtagene autoleucel). CRS was very mild and she achieved MRD-negative complete remission.
Read the full case →
Paediatric Lymphoma · Precision Chemotherapy · 15 May 2026
Patient Voices | A teenager with T-lymphoblastic lymphoma travels north for treatment and reaches CR — his father becomes a "research-minded parent"
In January 2025, 15-year-old Xiao Hao from Jiangsu was diagnosed with T-lymphoblastic lymphoma. After four cycles of an adult-protocol chemotherapy at a provincial hospital, the family travelled to Beijing GoBroad Boren Hospital, where Prof. Zhang Yonghong's team re-staged the disease as stage III CNS2 and switched him to the paediatric CNCL-NHL-2017-LBL high-risk protocol with bortezomib. By February 2026 he was in sustained deep remission and had entered maintenance therapy.
Read the full case →
Paediatric Lymphoma · Risk-Stratified Chemotherapy + Targeted Therapy · 15 April 2026
Patient Voices | A 9-year-old girl with high-risk T-lymphoblastic lymphoma/leukaemia completes intensive chemotherapy and enters maintenance
In April 2025, nine-year-old "Mango" was diagnosed with T-lymphoblastic lymphoma/leukaemia. Her family travelled to Beijing GoBroad Boren Hospital, where Prof. Zhang Yonghong's team found a NUP214-ABL1 fusion and bulky mediastinal disease with CNS involvement, classified her as high risk, and built an individualised paediatric high-risk chemotherapy plan combined with targeted therapy. She achieved complete remission with negative MRD and has now completed all intensive chemotherapy, entering an 18-month maintenance phase with a TKI.
Read the full case →
Stem Cell Transplant · Thalassaemia · 15 March 2026
Patient Voices | Free at last from lifelong transfusions — an 18-year-old with thalassaemia major restarts a healthy life
Diagnosed with beta-thalassaemia major before he was seven months old, A-Guang spent fifteen years bound to transfusion bags and iron chelation. After a matched unrelated donor withdrew at the last moment, the family waited years for technology to catch up. In the summer of 2025, just after his university offer arrived, he received a PTCy haploidentical transplant from his sister under Dr Liao Jianyun at GoBroad Chunfu Institute of Haematology. Five months on, all indicators are normal, his haemoglobin is stable at 120 g/L, and he plans to start university next September.
Read the full case →
Allogeneic Transplant · Acute Lymphoblastic Leukaemia · 15 February 2026
Patient Voices | Three years after her leukaemia transplant, she walked out of the ward and embraced a wider world
Wenwen, a young woman from northern China, was diagnosed with acute lymphoblastic leukaemia in 2022 after months of unexplained leg pain. She travelled to GoBroad Shanghai Zhaxin Hospital, achieved complete remission after two cycles of chemotherapy, and in November that year received an allogeneic transplant from her fully HLA-matched elder sister. She came through severe intestinal graft-versus-host disease and now, three years on, has passed her three-year review and is back to shopping with friends, riding her scooter and planning a new career.
Read the full case →
Allogeneic Transplant · Adult Acute Lymphoblastic Leukaemia · 15 January 2026
Patient Voices | Five years in complete remission — one adult ALL patient's recovery after a stem cell transplant
Mr Li, now 60, was diagnosed with acute lymphoblastic leukaemia at the end of 2019. A severe influenza-triggered lung infection after his first chemotherapy cycle nearly cost him his life, until he was transferred to GoBroad Shanghai Zhaxin Hospital. He achieved complete remission after induction chemotherapy with negative minimal residual disease, and in June 2020 received a fully matched allogeneic haematopoietic stem cell transplant from his younger sister. Five years on, the hospital held a warm "graduation ceremony" and awarded him a commemorative badge — and he shares exactly how his self-discipline at home protected his recovery.
Read the full case →
Allogeneic Transplant · Ph+ ALL · 15 December 2025
Patient Voices | Told she might not survive 15 days: a high-risk Ph-positive leukaemia patient returns to the classroom five years after transplant
In October 2019, 30-year-old primary school teacher Yuanyuan (pseudonym) was diagnosed with Ph-positive acute lymphoblastic leukaemia and told she might not survive 15 days. Multi-line therapy near home never cleared the BCR-ABL1 fusion gene. In May 2020 she travelled to Beijing GoBroad Boren Hospital, where the transplant team of Prof. Wu Tong and Dr. Song Yanzhi used an intensified conditioning regimen followed by an unrelated-donor allogeneic haematopoietic stem cell transplant. Five years on, all indicators remain stable and she has been back teaching for two years.
Read the full case →
Adult Leukaemia · CAR-T Cell Therapy · 15 September 2025
Patient Voices | Nine years in complete remission after CD19 CAR-T for B-ALL: he has helped thousands with his own hands — "If I survive, I will help many people"
In the summer of 2016, 29-year-old A-Feng was diagnosed with acute B-lymphoblastic leukaemia with myeloid expression. Chemotherapy failed repeatedly, a first attempt at CAR-T did not work, and although he completed a haploidentical stem cell transplant in June 2017, the disease relapsed just four and a half months later. In December 2017 he came to Beijing GoBroad Boren Hospital and the immunotherapy team of Prof. Tong Chunrong and Dr Lin Yuehui. Fifteen days after CD19 CAR-T infusion his marrow was in complete remission with negative MRD — a state that has now lasted almost nine years. Since early 2018 he has returned to the hospital every month as a volunteer, giving free tuina massage to exhausted staff and patient families: thousands of people over nearly nine years.
Read the full case →
Targeted Therapy · Advanced Gastric Cancer · 19 August 2025
Patient Voices | After multiple lines of therapy failed in advanced gastric cancer, she improved on CLDN18.2-targeted treatment
Diagnosed with advanced gastric cancer at 40, Chen Li spent four years in surgery, chemotherapy and immunotherapy, ending in intestinal obstruction, peritoneal metastasis, hydronephrosis and a bilirubin twenty times the upper limit. She weighed just over 30 kg and arrived at Shanghai GoBroad Cancer Hospital in a wheelchair. Her tumour was HER2-negative but CLDN18.2-positive — a target the family had waited three years for. In February 2025 Prof. Zhou Jun's team started an individualised CLDN18.2-targeted regimen; within weeks her obstruction eased, she began eating again, and by December 2025 she was slowly finishing a plate of pan-fried buns.
Read the full case →More cases will be added. Individual results vary; these stories are shared for general information and are not a substitute for personal medical diagnosis or treatment.
Free Case Feasibility Assessment
Start your medical journey to China
Based in Hong Kong and serving international patients, Privilege Medical bridges you to leading Class 3A and JCI-accredited hospitals in mainland China. We do not provide medical care directly — we coordinate specialist matching, medical visa support and on-the-ground concierge from your first enquiry to post-treatment follow-up.
Complete the form below. Our coordination team responds within 1–2 business days with a complimentary assessment covering clinical feasibility, specialist matching and an indicative admission timeline.
Privacy Notice
Privilege Medical is a Hong Kong–based medical concierge and does not provide clinical care. Personal data and medical information you submit are collected, held and used strictly for the purposes of case assessment, specialist matching and coordination of medical services in mainland China, in accordance with the Personal Data (Privacy) Ordinance (Cap. 486) of Hong Kong.
Your data may be transferred to our partner hospitals, treating clinicians and authorised service providers (including translators and travel coordinators), some of whom are located outside Hong Kong. We take reasonable steps to keep your information confidential and secure, and we do not sell your data to any third party.
You have the right, under the PDPO, to request access to and correction of the personal data we hold about you, and to withdraw consent at any time by writing to service@privilegemedical.com. Information submitted via this form is not encrypted end-to-end; please avoid including highly sensitive identifiers (e.g. ID numbers) in the free-text fields.